Lu-139Homo sapiens (Human)Cancer cell line

Also known as: LU139, Lu139, LU-139, NCC-c-Lu-139

🤖 AI SummaryBased on 12 publications

Quick Overview

Human lung cancer cell line with known mutations in DCC and p53 genes.

Detailed Summary

Lu-139 is a human lung cancer cell line derived from small cell lung carcinoma (SCLC). It is characterized by specific genetic alterations, including mutations in the DCC gene and p53 gene. The DCC gene, located on chromosome 18q21, is involved in tumor suppression, and mutations in this gene have been associated with various cancers. Additionally, p53 mutations are common in lung cancers and play a critical role in cell cycle regulation and apoptosis. These genetic alterations make Lu-139 a valuable model for studying the molecular mechanisms of lung cancer progression and for testing therapeutic strategies targeting these pathways.

Research Applications

Cancer geneticsTumor suppressor gene analysisp53 mutation studiesDCC gene mutation analysis

Key Characteristics

Mutations in DCC geneMutations in p53 geneSmall cell lung carcinoma origin
Generated on 6/16/2025

Basic Information

Database IDCVCL_1390
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age63
Age CategoryAdult
SexMale

Disease Information

DiseaseSmall cell lung cancer
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeRIKEN
Source IDACH-002052_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Val157Phe (c.469G>T)Homozygous-Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11
D13S317
11
D16S539
9
D5S818
13
D7S820
12
TH01
9
TPOX
8,12
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.

Kasai F., Fukushima M., Miyagi Y., Nakamura Y.

Hum. Cell 37:944-950(2024).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Pathol. Res. Pract. 201:109-115(2005).

A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.

Inazawa J.

Am. J. Pathol. 161:207-216(2002).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

J. Cancer Res. Clin. Oncol. 120:143-148(1994).

Changes in cell characteristics due to culture conditions in cell lines from human small cell lung cancer.

Hirohashi S., Yamaguchi K., Kato K., Ichinose H., Nagatsu T.

Jpn. J. Clin. Oncol. 16:203-212(1986).

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Saijo N.

Cancer Chemother. Pharmacol. 27:263-270(1991).

Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.

Sugimura T., Terada M., Yokota J.

Oncogene 7:451-457(1992).